Beeley LJ, Duckworth DM. 1996. The impact of geno-
mics on drug design.Drug Discov. Today 1 (11):
474–480.
Chapman D. 1996. The measurement of molecular
diversity: a three dimensional approach.J. Com-
put.-Aided Mol. Des. 10 : 501–512.
Goffeau A,et al. 1996. Life with 6000 genes.Science
274 : 546–567.
Kozlowski MR. 1996. Problem solving in laboratory
automation.Drug Discov. Today 1 (11): 481–488.
Lipinski CA,et al. 1997. Experimental and computa-
tional approaches to estimate solubility and perme-
ability in drug discovery and development settings.
Adv. Drug Deliv. Rev. 23 : 3–29.
Lipper RA. 1999. How can we optimize selection of
drug development candidates from many com-
pounds at the discovery stage?Mod. Drug Discov.
2 (1): 55–60.
Pericak-Vance MA, Bebout JL, Gaskell PC,et al. 1991.
Linkage studies in familial Alzheimer disease: evi-
dence for chromosome 19 linkage.Am. J. Hum.
Genet. 48 : 1034–1050.
Schuler GD,et al. 1996. A gene map of the human
genome.Science 274 : 540–546.
Van Drie JH. 1997. Strategies for the determination of
pharmacophoric 3D database queries.J. Comput.-
Aided Mol. Des. 11 : 39–52.
Wainer IW. 1993. Stereoisomers in clinical oncology:
why it is important to know what the right and
left hands are doing. Ann. Oncol. 4 (Supp 2):
7–13.Further Reading
Beeley LJ, Duckworth DM. 1996. The impact of geno-
mics on drug design.Drug Discov. Today 1 (11):
474–480.
Bugrim A, Nikolskaya T, Nikolsky Y. 2004.Drug
Discov. Today 9 : 127–135.
Chapman D. 1996. The measurement of molecular
diversity: a three dimensional approach.J. Computer-
Aided Mol. Des. 10 : 501–512.
Downward J. 2002. Targeting RAS signaling
pathways in cancer therapy.Nat. Rev.: Cancer 3 :
11–21.
Goffeau A,et al.1996. Life with 6000 genes.Science
274 : 546–567.
Kozlowski MR. 1996. Problem solving in laboratory
automation.Drug Discov. Today 1 (11): 481–488.
Schuler GD,et al.1996. A gene map of the human
genome.Science 274 : 540–546.50 CH4 DRUG DISCOVERY: DESIGN AND SERENDIPITY